2 September 2024
Hemogenyx Pharmaceuticals
plc
("Hemogenyx Pharmaceuticals" or the "Company")
CDX Development
Update
Hemogenyx Pharmaceuticals plc
(LSE: HEMO), a clinical-stage biopharmaceutical group focused on developing
treatments for cancers and viral diseases, is pleased to announce
that it has developed a new and improved version of its bi-specific
antibody ("CDX") for the treatment of relapsed/refractory acute
myeloid leukaemia ("AML"), a subset of acute lymphoblastic
leukaemia ("ALL"), and potentially for conditioning in bone marrow
transplantations.
The
Company's scientists utilised Lonza's bYlok
bispecific pairing technology to develop a new and
improved version of CDX, which has demonstrated significantly
enhanced efficacy in in
vitro testing. Additional in vivo studies are currently
underway.
Dr. Vladislav Sandler, CEO
and Co-Founder of Hemogenyx Pharmaceuticals,
commented:
"The
development of an improved version of our CDX bi-specific antibody
holds significant promise for enhancing treatment outcomes for
patients battling often incurable blood cancers. This advancement
could accelerate the progress of this product candidate and allow
us to resume its development toward the clinic. It may also attract
new industry partners interested in fast-tracking the
co-development of CDX."
Enquiries:
|
Hemogenyx Pharmaceuticals plc
|
https://hemogenyx.com
|
|
Dr Vladislav Sandler, Chief
Executive Officer & Co-Founder
|
headquarters@hemogenyx.com
|
|
Peter Redmond, Director
|
peter.redmond@hemogenyx.com
|
|
|
|
|
SP
Angel Corporate Finance LLP
|
Tel: +44 (0)20 3470 0470
|
|
Matthew Johnson, Vadim Alexandre,
Adam Cowl
|
|
|
|
|
|
Peterhouse Capital Limited
|
Tel: +44 (0)20 7469 0930
|
|
Lucy Williams, Duncan Vasey, Charles
Goodfellow
|
|
About Hemogenyx
Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a
publicly traded company (LSE: HEMO) headquartered in London, with
its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and
Immugenyx LLC, located in New York City at its state-of-the-art
research facility.
The Company is a clinical-stage
biopharmaceutical group developing new medicines and treatments for
life-threatening diseases. Hemogenyx Pharmaceuticals is developing
several distinct and complementary product candidates, as well as a
platform technology that it uses as an engine for novel product
development.
About
AML
AML, the most common type of acute
leukemia in adults, has poor survival rates (a five-year survival
rate of less than 30% in adults) and is currently treated using
chemotherapy, rather than the potentially more benign and effective
form of therapy being developed by Hemogenyx Pharmaceuticals. The
successful development of the new therapy for AML would have a
major impact on treatment and survival rates for the
disease.
About ALL
Acute Lymphoblastic Leukemia (ALL)
is a cancer of the blood and bone marrow that primarily affects
children, although it can also occur in adults. Unlike Acute
Myeloid Leukemia (AML), ALL is characterized by the rapid
proliferation of immature lymphocytes, a type of white blood cell.
ALL is the most common childhood cancer, representing approximately
25% of cancer diagnoses in children. It progresses quickly and
requires prompt treatment. While the overall prognosis for ALL
is generally more favorable than AML, certain subtypes remain
challenging to treat. Hemogenyx Pharmaceuticals is developing
innovative treatments specifically targeting a subset of ALL that
has proven particularly difficult to treat, especially in children.
The Company's R&D focuses on addressing the limitations of
current therapies and improving outcomes for patients with these
hard-to-treat forms of ALL.